Lauris Gastaud
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lauris Gastaud has a total of 146 co-authors. Here are the top co-authors by number of shared publications:
- Céline Berthon
Hematology Department, CHRU Lille, Lille, France
28 shared publications - Emilie Lemasle
18Department of Hematology, Henri-Becquerel Cancer Center, Rouen, France
28 shared publications - Hervé Dombret
Saint Louis Hospital, University of Paris, Paris, France
28 shared publications - Jean-Baptiste Micol
Gustave Roussy, Villejuif, France
28 shared publications - Lionel Adès
AP-HP, Hôpital Saint Louis and University of Paris, INSERM U944 and THEMA insitute, Paris, France
28 shared publications - Sylvain Chantepie
University Hospital, Caen, France
28 shared publications
Latest Publications
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience
Commutation plot visualizing the mutated genes in t-MN after OC according to PARPi treatment.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience
Commutation plot visualizing the mutated genes in t-MN after OC according to PARPi treatment.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience
TP53 mutations characteristics among t-MN PARPi national cohort.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience
TP53 mutations characteristics among t-MN PARPi national cohort.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience
Flow chart of the study displaying the three cohorts.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience
Flow chart of the study displaying the three cohorts.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience
Waffle chart (%) of patients addressed for cytopenia exploration after OC exposed to a PARPi treatment from cytopenia diagnosis (A) and cytopenia diagnosis based on NGS results (B). Dot plots (C) showing the median WBC, hemoglobin, and platelet counts from patients referred for cytopenia exploration after OC exposed to a PARPi treatment according to t-MN diagnosis (“t-MN”) or not (“Cytopenia”).
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience
Waffle chart (%) of patients addressed for cytopenia exploration after OC exposed to a PARPi treatment from cytopenia diagnosis (A) and cytopenia diagnosis based on NGS results (B). Dot plots (C) showing the median WBC, hemoglobin, and platelet counts from patients referred for cytopenia exploration after OC exposed to a PARPi treatment according to t-MN diagnosis (“t-MN”) or not (“Cytopenia”).
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience
Blood smear and bone marrow aspiration of patient referred for cytopenia post PARPi.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience
Blood smear and bone marrow aspiration of patient referred for cytopenia post PARPi.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience
Patient characteristics of the national cohort according to the type of PARPi received (olaparib vs. other PARP inhibitors).
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience
Patient characteristics of the national cohort according to the type of PARPi received (olaparib vs. other PARP inhibitors).
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience
Univariate analysis for overall survival from t-MN diagnosis of patients from the national cohort.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience
Univariate analysis for overall survival from t-MN diagnosis of patients from the national cohort.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience
Univariate analysis for overall survival from t-MN diagnosis of patients diagnosed with t-MN after OC according to PARPi exposure.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience
Univariate analysis for overall survival from t-MN diagnosis of patients diagnosed with t-MN after OC according to PARPi exposure.
- Open Access
- 3 October 2023
- Published by Elsevier in Bulletin du Cancer
- Vol. 110 (12) , 1232-1233
Ivosidenib–azacitidine dans les leucémies aiguës myéloïdes avec mutation IDH1 R132
- 3 October 2023
- Published by Elsevier in Bulletin du Cancer
- Vol. 110 (12) , 1232-1233
Open AccessIvosidenib–azacitidine dans les leucémies aiguës myéloïdes avec mutation IDH1 R132
- 25 September 2023
- Published by Elsevier in Journal Français d'Ophtalmologie
- Vol. 47 (1) , 103958
Can 18F-FDG PET/CT findings be used to predict orbital tumor histology?
- 25 September 2023
- Published by Elsevier in Journal Français d'Ophtalmologie
- Vol. 47 (1) , 103958
Can 18F-FDG PET/CT findings be used to predict orbital tumor histology?